Day One Biopharma's OJEMDA FDA approval for pediatric glioma, but market concerns remain. Check out why I rate DAWN stock as ...

Wolfe Research initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating.Maximize Your Portfolio with Data Driven ...

AdvanCell, an Australia-based radiopharmaceutical company, has raised $112m as investor interest in the radiopharma sector ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

The Banks Public Private Partnership, a joint venture of the city of Cincinnati and Hamilton County, has issued a new call ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

IQVIA Holdings Inc. (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services for the healthcare and life sciences industries, finds itself at a critical ...

Aeon Biopharma Inc’s profitability metrics reveal strong financial health. The company currently boasts a gross margin of -92.52%. The profit margin, also known as the revenue ratio or gross profit ...

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Aardvark Therapeutics plans a $100M IPO for metabolic treatments, targeting rare Prader-Willi syndrome with a potential ...

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, highlights how the ...